Citalopram

證據等級: L5

預測適應症: 5 個

Citalopram: From Major Depressive Disorder to Obsessive-Compulsive Disorder

One-Sentence Summary

Citalopram is a selective serotonin reuptake inhibitor (SSRI) widely used internationally for the treatment of major depressive disorder. The TxGNN model predicts it may be effective for Obsessive-Compulsive Disorder (OCD), with 30 clinical trials and 16 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Major depressive disorder (global use; not registered in Italy)
Predicted New Indication	Obsessive-Compulsive Disorder (OCD)
TxGNN Prediction Score	99.74%
Evidence Level	L2
Italy Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known pharmacology, Citalopram is a racemic SSRI — it inhibits the serotonin transporter (SERT), thereby increasing synaptic serotonin concentrations in the central nervous system. Its active S-enantiomer, escitalopram, is the component responsible for the primary therapeutic effect and has been extensively studied in its own right.

OCD's pathological core involves dysfunction of the cortical–striatal–thalamic–cortical (CSTC) circuit, where serotonin plays a key modulatory role in regulating intrusive thoughts and compulsive behaviors. By elevating synaptic serotonin, SSRIs dampen the hyperactivation of this circuit, producing symptomatic relief. This is precisely the mechanism underlying the approved OCD indications of fluoxetine, fluvoxamine, paroxetine, and sertraline — all members of the same pharmacological class as citalopram.

The mechanistic bridge is further strengthened by the direct relationship between citalopram and escitalopram: escitalopram is the purified active enantiomer of citalopram, making the extensive escitalopram OCD trial evidence highly translatable. Moreover, citalopram itself has been directly studied in treatment-resistant OCD (PMID 10572334), with a 90-day open-label trial demonstrating measurable Y-BOCS score reduction. The TxGNN prediction score of 99.74% is therefore well anchored in both mechanism and clinical observation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00305500	Phase 3	Completed	100	Tolerability and efficacy of high-dose escitalopram (up to 50 mg/d) in OCD outpatients over 18 weeks; dose-escalation design
NCT00723060	Phase 4	Completed	176	Randomized double-blind multi-center comparison of conventional (20 mg) vs high-dose (40 mg) escitalopram in OCD; primary endpoint Y-BOCS
NCT00074815	Phase 3	Completed	124	CBT augmentation of SRI treatment in children with OCD who had partial SRI response; compared therapist types
NCT00680602	Phase 4	Completed	158	Group CBT vs SSRI (fluoxetine) in real-world OCD patients including those with psychiatric comorbidities; randomized open trial
NCT02022709	Phase 4	Completed	78	ERP vs SSRIs vs combination in OCD; identified biological and psychological treatment-response predictors in Chinese population
NCT00116532	Phase 4	Completed	30	Assessed efficacy and optimal treatment dose of escitalopram for OCD
NCT03993535	Phase 4	Completed	250	Large-scale naturalistic follow-up examining clinical, neurocognitive, and neuroimaging variables predicting OCD treatment response
NCT01404871	N/A	Completed	26	Randomized comparison of clomipramine vs escitalopram in OCD; explored biomarkers predicting differential medication response
NCT04336228	Phase 4	Active, not recruiting	46	Mechanistic study: serotonin's role in compulsive behavior; how sub-chronic escitalopram affects 5-HT system and goal-directed cognition
NCT02285699	N/A	Completed	43	Gut microbiota and serum inflammatory markers in OCD patients vs healthy controls; changes following 12-week open-label SSRI treatment

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38703743	2024	Systematic Review / Meta-analysis	Comprehensive Psychiatry	Long-term safety and tolerability of off-label high-dose SRIs in OCD; supports dose escalation strategy beyond standard limits
35121274	2022	Meta-analysis	J Psychiatric Research	Network meta-analysis comparing pharmacological vs psychological treatments (alone/combined) in pediatric OCD; SSRIs show consistent efficacy
28477500	2017	Meta-analysis	J Affective Disorders	OCD shows a smaller placebo (and antidepressant) response compared to other anxiety disorders; highlights need for higher SSRI doses and longer trials
32982805	2020	Meta-review	Frontiers in Psychiatry	Comprehensive meta-review of antidepressants (including SSRIs) in children/adolescents across psychiatric conditions including OCD; benefit-risk summary
22305974	2012	Review	BMJ Clinical Evidence	OCD overview: ~1–2% adult prevalence, episodic and chronic courses; SSRIs and CBT as first-line treatments; updates clinical management framework
10572334	1999	Open-label Trial	European Psychiatry	Direct citalopram evidence: 90-day randomized open-label trial of citalopram vs citalopram+clomipramine in treatment-resistant OCD (n=16); Y-BOCS reductions observed
10471169	1999	Clinical Report	Int Clinical Psychopharmacology	Direct citalopram evidence: narrative clinical review linking citalopram to OCD treatment; discusses serotonergic mechanism in context of OCD neurobiology
34313207	2022	Clinical Study	CNS Spectrums	BDNF Val66Met polymorphism modulates response to escitalopram/paroxetine in OCD; supports precision-medicine framework for SSRI selection in OCD
30973183	2019	Clinical Study	Psychiatry & Clinical Neurosciences	¹H-MRS neurochemical changes in 28 unmedicated OCD patients before and after 12-week escitalopram treatment; demonstrates measurable brain-level drug response
35818708	2022	Systematic Review	Expert Opinion Pharmacotherapy	Systematic review of RCTs for OCPD pharmacotherapy; provides context on SSRI efficacy across OCD-spectrum conditions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3/4 trials support escitalopram — the direct active enantiomer of citalopram — in OCD, and two independent meta-analyses confirm SSRI class efficacy in this indication. Citalopram itself has direct open-label trial evidence in treatment-resistant OCD, making the mechanistic and clinical case for repurposing highly credible.

To proceed, the following is needed:

Safety profile completion: Retrieve full Italian package insert (or EMA SmPC equivalent) to populate contraindications, key warnings, and QTc prolongation risk (a known class concern for citalopram at high doses)
DDI profile: Conduct formal drug–drug interaction assessment, particularly with antipsychotics and other serotonergic agents commonly co-prescribed in OCD
Dose optimization: Define citalopram OCD dosing protocol by cross-referencing escitalopram dose-escalation studies (typical escitalopram OCD doses of 20–40 mg/d correspond to citalopram 40–80 mg/d), with cardiac monitoring plan for doses above 40 mg/d
AIFA registration pathway: Determine whether an off-label use authorization, an extension of indication, or a 648/96 Law exemption applies for OCD in Italy
Pediatric considerations: If OCD in children/adolescents is within scope, a dedicated risk assessment is needed given regulatory restrictions on SSRI use in this population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.